CA3300004A1 - Formulations pharmaceutiques de bictégravir et de lénacapavir - Google Patents

Formulations pharmaceutiques de bictégravir et de lénacapavir

Info

Publication number
CA3300004A1
CA3300004A1 CA3300004A CA3300004A CA3300004A1 CA 3300004 A1 CA3300004 A1 CA 3300004A1 CA 3300004 A CA3300004 A CA 3300004A CA 3300004 A CA3300004 A CA 3300004A CA 3300004 A1 CA3300004 A1 CA 3300004A1
Authority
CA
Canada
Prior art keywords
lenacapavir
bictegravir
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3300004A
Other languages
English (en)
Inventor
Priyanka Arora
Marina A. Clampffer
Julie A. Fogarty
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CA3300004A1 publication Critical patent/CA3300004A1/fr
Pending legal-status Critical Current

Links

CA3300004A 2023-08-15 2024-08-14 Formulations pharmaceutiques de bictégravir et de lénacapavir Pending CA3300004A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63/519,675 2023-08-15
EP23201068.6 2023-09-29

Publications (1)

Publication Number Publication Date
CA3300004A1 true CA3300004A1 (fr) 2025-02-20

Family

ID=

Similar Documents

Publication Publication Date Title
EP4297741A4 (fr) Méthodes et formulations pour l'administration topique de gabapentinoïdes
HK40122888A (en) Pharmaceutical formulations of bictegravir and lenacapavir
CA3266804A1 (fr) Composition pharmaceutique et son utilisation
PL4531816T3 (pl) Formulacje farmaceutyczne biktegrawiru oraz lenakapawiru
EP4157262A4 (fr) Formulations pharmaceutiques de pilocarpine r-(+)-lipoate
HK40121460A (en) Pharmaceutical compositions of mosunetuzumab and methods of use
HK40131600A (en) Pharmaceutical formulations and uses thereof
AU2024902868A0 (en) Pharmaceutical Formulations and Uses Thereof
CA3304242A1 (fr) Formulations pharmaceutiques comprenant du 5-meo-dmt et leurs utilisations thérapeutiques
HK40113484A (en) Pharmaceutical preparation and application thereof
HK40130528A (en) Combined pharmaceutical composition of substituted 2-hydrogen-pyrazole derivative and use thereof
CA3281828A1 (fr) Composition pharmaceutique combinée de dérivé de 2-hydrogène-pyrazole substitué et son utilisation
CA3276109A1 (fr) Formulations et procédés d'utilisation
CA3305014A1 (fr) Formulation pharmaceutique solide orale d'enzalutamide
HK40104596A (en) Centanafadine pharmaceutical formulations, and methods of making and using same
HK40123008A (en) High dose endoxifen formulations and methods of use
HK40089929A (zh) 药物制剂及其用途
CA3277917A1 (fr) Formulations pharmaceutiques liquides de tafamidis
CA3278196A1 (fr) Formulations orales liquides de nétupitant et de palonosétron
AU2023421785A1 (en) Liquid oral formulations of netupitant and palonosetron
CA3273940A1 (fr) Compositions pharmaceutiques contenant de la doravirine et de l'islatravir
AU2023902710A0 (en) Pharmaceutical compositions and methods
CA3304568A1 (fr) Compositions pharmaceutiques contenant du maralixibat et leurs utilisations
AU2022903010A0 (en) Pharmaceutical compositions and methods
CA3309483A1 (fr) Composition pharmaceutique et utilisation associee